Alnylam Grants Dharmacon License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
Alnylam's intellectual property estate includes certain "fundamental" patents and patent applications that claim broad structural and functional properties of synthetic RNAi products. This fundamental intellectual property includes the Kreutzer-Limmer patent family that was obtained through the July 2003 acquisition of Ribopharma AG, now Alnylam Europe AG. The Kreutzer-Limmer family includes: EP Patent No. 1144623, covering siRNAs up to 25 nucleotides in length having a sequence complementary to a target gene; and EP Patent No. 1214945, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides. Patents corresponding to these European patents have been issued or are pending in many other countries.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.